Statins, myalgia, and rhabdomyolysis

Area of Science:

• Pharmacology
• Muscle Biology
• Cardiovascular Medicine

Background:

• Statin-associated muscle symptoms (SAMSs) present a spectrum of muscle issues, from myalgia to rhabdomyolysis.
• Myalgia with elevated creatine kinase (CK) is the most frequent SAMS presentation, typically emerging within a month of statin initiation.

Purpose of the Study:

• To explore the mechanisms underlying statin-induced muscle injury.
• To discuss the risk-benefit balance of statin therapy, especially in patients with comorbidities like inflammatory rheumatic diseases.
• To outline management strategies for SAMS, including alternative lipid-lowering drugs and diagnostic approaches for severe cases.

Main Methods:

• Review of existing literature on statin pharmacology and myotoxicity.
• Analysis of factors contributing to muscle injury, including drug accumulation, genetic susceptibility, and drug interactions.
• Discussion of clinical presentations, diagnostic criteria, and therapeutic options for SAMS.

Main Results:

• SAMS mechanisms involve statin accumulation, muscle fragility, altered metabolism, and potential autoimmune triggers.
• HMG-CoA reductase inhibition affects muscle energy, mitochondria, lipid oxidation, apoptosis, and protein synthesis.
• Severe SAMS may indicate necrotizing autoimmune myopathy, requiring specific diagnostic tests and immunosuppression.

Conclusions:

• Statin therapy is crucial for high cardiovascular risk, but risks must be weighed against benefits.
• Management involves dose adjustment, switching statins, or considering alternative lipid-lowering agents.
• Prompt diagnosis and treatment, including immunosuppression for necrotizing autoimmune myopathy, are vital in severe SAMS cases.